Evolving chemotherapeutics

Posts by rdranson

BIO 2021

FivepHusion will be attending and presenting at BIO Digital 2021, on June 14-18. As it prepares for its phase III pivotal registration trial, FivepHusion is seeking investment and strategic partners to pursue registration and commercialisation of Deflexifol™ as the new standard of care for solid tumor treatment.

Bridging Trial Recruiting at Dose Lev...

The bridging PK study of Deflexifol is progressing well. Study chief investigator Associate Professor Daniel Brungs reports that patients are being recruited to Dose Level 4. 14 patients have been treated so far. The study appears to reinforce earlier findings about the safety and tolerability of Deflexifol – with patients tolerating 40% higher dosing than […]

Bridging trial underway

The bridging PK study of Deflexifol is reported to be progressing well. Sponsored by Detsamma Investments under an out-license from FivepHusion, the clinical trial is being undertaken at the Southern Medical Day Care Centre in Wollongong, Australia. Study chief investigator Associate Professor Daniel Brungs reports that patients are still being recruited to Dose Level 2, […]

Detsamma and FivepHusion to begin bri...

Detsamma Investments and its partner FivepHusion have received human ethics approval to begin its bridging PK study of Deflexifol. This study will gather improved PK data and further efficacy signals in a regimen that matches SOC for 5-FU and Leucovorin.

New partnership to fund Deflexifol br...

Fivephusion has concluded a drug development partnership deal with Detsamma Investments Pty Ltd. Detsamma will fund the further development of Deflexifol, including completing a bridging trial to gather extra data sought by the FDA. Detsamma Investments plans to complete the bridging trial in 2020, and follow this with a pre-IND meeting with the FDA. Detsamma […]

David Ranson presents at Ausbiotech I...

David Ranson presents at Ausbiotech Invest conference

David Ranson presented the Deflexifol opportunity at the recent Ausbiotech Invest and Partnering 2018 conference in Melbourne, Australia (http://ausbiotechinvestment.com.au/australia-biotech-invest/event-details)

Bio-Link to assist FivepHusion with B...

Bio-Link to assist FivepHusion with Business Development

FivepHusion have engaged Bio-Link Australia to assist with business development and out-licensing opportunities for Deflexifol. Bio-Link (http://bio-link.com/) is a strategic consulting and biotechnology business development company that works with Australian and international life sciences companies and academic institutions to facilitate deals based on strategic technology analysis and consulting, business development, project management and deal negotiation.

ASCO 2017 – Detailed clinical t...

ASCO 2017 – Detailed clinical trial results presented

The phase 1 trial results were presented in greater detail in two posters at ASCO 2017 in Chicago this week. Professor Phil Clingan presented a poster: Deflexifol (a novel formulation of 5FU) Phase 1 Dose Escalation Study of Infusional or Bolus Schedules After Failure of Standard Treatment Clingan P. et al J Clin Oncol 35, 2017 […]

David Ranson to join Ausbiotech’...

David Ranson to join Ausbiotech’s Asian Investment Series in March 2017

David Ranson will be presenting the Deflexifol opportunity to potential investors in Singapore, Hong Kong and Shanghai as part of AusBiotech’s Asian Investment Series, March 21 – 28, 2017. See http://ausbiotechinvestment.com.au/ for more details.

Trial results presented at ASCO GI, 2...

Trial results presented at ASCO GI, 2017

A poster presentation by Professor Phil Clingan summarizing phase 1 results has been presented at the ASCO GI conference, San Francisco, January 19-21, 2017. J Clin Oncol 35, 2017 (suppl 4S; abstract TPS812)